Tampa, FL – November 20, 2006 – Pilgrim Software, Inc., a world-leading provider of Enterprise Compliance and Quality Management (ECQM) software solutions, today announced that Genzyme Corporation (NASDAQ: GENZ) has begun the worldwide rollout of Pilgrim’s SmartCAPA solution at multiple sites and divisions across the United States.  The enterprise-wide CAPA management system will be live across Genzyme’s global operations by the year’s end. 

Genzyme selected SmartCAPA to provide a common platform for managing deviations and resulting CAPA activities, and to standardize its global CAPA processes.  This fall, Genzyme, having implemented a common workflow CAPA process across its other facilities and divisions, prepared to conduct rolling deployments of SmartCAPA at its sites worldwide.

SmartCAPA is designed specifically to address the corrective action/preventive action, non-conformance processes and products of an entire organization from the administrative office to the product floor. It manages the complete cycle of action from the detection phase to the final resolution of the issue. 

“Pilgrim consultants worked closely with Genzyme to complete the global migration of data from their existing SmartCAPA system to the next enterprise level within four months,” said Steve Demmi, Pilgrim’s Vice President of Operations.  “The efficient migration enabled Genzyme to quickly begin realizing the benefits of our scalable CAPA management system built on a common workflow process across the entire enterprise.

With a common workflow in place across all its sites and divisions, Genzyme will maintain ongoing management oversight into quality and compliance issues.  With further improvements to its CAPA process efficiencies, the company will realize overall cost savings and sustain a high level of customer satisfaction, further solidifying Genzyme’s reputation as a reliable supplier.

“In addition to driving functional improvements to internal CAPA processes,” Demmi said, “Genzyme can rest assured that the enterprise-wide implementation of SmartCAPA will support its compliance with FDA requirements at every one of its sites as well.”

Genzyme’s global enterprise will be live with the Pilgrim’s SmartCAPA solution by the end of November.

About Genzyme
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Founded in 1981 as a small start-up company, Genzyme today provides many established products and services helping patients in more than 80 countries.  Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields as well as heart disease and other areas of unmet medical need. For more information about Genzyme, visit their website at www.genzyme.com.

About Pilgrim Software, Inc.
Pilgrim Software, Inc. is the leading provider of Enterprise Compliance and Quality Management solutions for global organizations. Pilgrim helps organizations manage industry and regulatory compliance, reduce manufacturing costs and improve customer satisfaction. For more information, visit Pilgrim Software’s Web site at www.pilgrimsoftware.com.